DK1414816T3 - Stabil polymorf af flibanserin, teknisk fremgangsmåde til fremstilling deraf og anvendelse deraf til lægemiddelfremstilling - Google Patents

Stabil polymorf af flibanserin, teknisk fremgangsmåde til fremstilling deraf og anvendelse deraf til lægemiddelfremstilling

Info

Publication number
DK1414816T3
DK1414816T3 DK02767277T DK02767277T DK1414816T3 DK 1414816 T3 DK1414816 T3 DK 1414816T3 DK 02767277 T DK02767277 T DK 02767277T DK 02767277 T DK02767277 T DK 02767277T DK 1414816 T3 DK1414816 T3 DK 1414816T3
Authority
DK
Denmark
Prior art keywords
preparation
flibanserin
technical process
stable polymorph
drug
Prior art date
Application number
DK02767277T
Other languages
English (en)
Inventor
Carlo Bombarda
Antoine Ezhaya
Enrica Dubini
Original Assignee
Bidachem Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bidachem Spa filed Critical Bidachem Spa
Application granted granted Critical
Publication of DK1414816T3 publication Critical patent/DK1414816T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
DK02767277T 2001-08-02 2002-07-30 Stabil polymorf af flibanserin, teknisk fremgangsmåde til fremstilling deraf og anvendelse deraf til lægemiddelfremstilling DK1414816T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01118593 2001-08-02
EP01130180 2001-12-19
EP02767277A EP1414816B1 (en) 2001-08-02 2002-07-30 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
PCT/EP2002/008466 WO2003014079A1 (en) 2001-08-02 2002-07-30 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments

Publications (1)

Publication Number Publication Date
DK1414816T3 true DK1414816T3 (da) 2005-04-11

Family

ID=26076670

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02767277T DK1414816T3 (da) 2001-08-02 2002-07-30 Stabil polymorf af flibanserin, teknisk fremgangsmåde til fremstilling deraf og anvendelse deraf til lægemiddelfremstilling

Country Status (27)

Country Link
EP (2) EP1414816B1 (da)
JP (1) JP3822601B2 (da)
KR (1) KR100899297B1 (da)
CN (1) CN1288147C (da)
AR (2) AR036208A1 (da)
AT (1) ATE288911T1 (da)
AU (1) AU2002331361B2 (da)
BR (1) BR0211601A (da)
CA (1) CA2450093C (da)
CO (1) CO5560572A2 (da)
DE (1) DE60202958T2 (da)
DK (1) DK1414816T3 (da)
EA (1) EA006400B1 (da)
ES (1) ES2237694T3 (da)
HK (1) HK1070063A1 (da)
HR (1) HRP20040107B1 (da)
HU (1) HU228666B1 (da)
IL (2) IL159151A0 (da)
MX (1) MXPA04000913A (da)
MY (1) MY127294A (da)
NZ (1) NZ530510A (da)
PL (1) PL210224B1 (da)
PT (1) PT1414816E (da)
RS (1) RS50742B (da)
SI (1) SI1414816T1 (da)
UA (1) UA76767C2 (da)
WO (1) WO2003014079A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
WO2003097058A1 (en) * 2002-05-22 2003-11-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pharmaceutical compositions containing flibanserin polymorph a
WO2006119884A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
JP2009513604A (ja) 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
CA2642368A1 (en) * 2006-02-28 2007-09-07 Boehringer Ingelheim International Gmbh Treatment of prevention of valvular heart disease with flibanserin
RS54398B1 (en) * 2006-05-09 2016-04-28 Sprout Pharmaceuticals, Inc. THE USE OF FLIBANSERINE FOR THE TREATMENT OF SEXUAL DESIRE DISORDERS IN POSTMENOPAUSE
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
KR20090042967A (ko) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EA200900270A1 (ru) 2006-08-25 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Системы регулируемого высвобождения и способ их приготовления
WO2008061966A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim International Gmbh New use of flibanserin
JP2010513390A (ja) 2006-12-20 2010-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 混合セロトニン受容体親和性を有する硫酸化ベンズイミダゾロン誘導体
EP1955699A1 (en) * 2007-02-08 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flibanserin for the treatment of insomnia
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
CA2686480A1 (en) * 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017076356A1 (zh) * 2015-11-05 2017-05-11 苏州晶云药物科技有限公司 氟班色林的新晶型及其制备方法
CN113683570A (zh) * 2016-01-31 2021-11-23 孟晓明 氟班色林的新晶型及其制备方法及其用途
CN111303043A (zh) * 2019-04-19 2020-06-19 武汉万知化工医药有限公司 一种氟班色林盐酸盐的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone

Also Published As

Publication number Publication date
BR0211601A (pt) 2004-08-24
HU228666B1 (en) 2013-05-28
HRP20040107B1 (en) 2012-02-29
JP3822601B2 (ja) 2006-09-20
PL210224B1 (pl) 2011-12-30
RS50742B (sr) 2010-08-31
MXPA04000913A (es) 2004-10-27
IL159151A0 (en) 2004-06-01
EA006400B1 (ru) 2005-12-29
EA200400252A1 (ru) 2004-08-26
ATE288911T1 (de) 2005-02-15
EP1414816A1 (en) 2004-05-06
HUP0401201A3 (en) 2004-11-29
WO2003014079A8 (en) 2003-11-20
YU7804A (sh) 2006-08-17
CN1551879A (zh) 2004-12-01
IL159151A (en) 2009-09-22
HUP0401201A2 (hu) 2004-10-28
DE60202958T2 (de) 2006-04-06
CO5560572A2 (es) 2005-09-30
EP1518858A1 (en) 2005-03-30
AR036208A1 (es) 2004-08-18
HK1070063A1 (en) 2005-06-10
SI1414816T1 (en) 2005-06-30
NZ530510A (en) 2004-07-30
AR077416A2 (es) 2011-08-24
UA76767C2 (uk) 2006-09-15
KR100899297B1 (ko) 2009-05-26
EP1414816B1 (en) 2005-02-09
HRP20040107A2 (en) 2004-06-30
MY127294A (en) 2006-11-30
KR20040023704A (ko) 2004-03-18
JP2004537597A (ja) 2004-12-16
AU2002331361B2 (en) 2008-06-05
PT1414816E (pt) 2005-04-29
DE60202958D1 (de) 2005-03-17
CN1288147C (zh) 2006-12-06
ES2237694T3 (es) 2005-08-01
CA2450093A1 (en) 2003-02-20
WO2003014079A1 (en) 2003-02-20
CA2450093C (en) 2008-09-23
PL364598A1 (en) 2004-12-13

Similar Documents

Publication Publication Date Title
DK1414816T3 (da) Stabil polymorf af flibanserin, teknisk fremgangsmåde til fremstilling deraf og anvendelse deraf til lægemiddelfremstilling
DK1330249T3 (da) Aripiprazol-lægemiddelstof med lav hygroskopicitet og fremgangsmåder til fremstilling deraf
DK1345910T3 (da) Quinazolinderivater, lægemidler indeholdende forbindelserne, deres anvendelse og fremgangsmåde til fremstilling deraf
DK1478339T3 (da) Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf
DK1448591T3 (da) 17-alpha-alkyl-17-beta-oxy-estratriener og mellemprodukter til fremstilling heraf, anvendelse af 17-alpha-alkyl-17-beta-oxy-estratriener til fremstilling af lægemidler samt farmaceutiske præparater
DK1523488T3 (da) Nye thiophenglycosidderivater, fremgangsmåder til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
NO20032438L (no) Ortosubstituerte og metasubstituerte bisarylforbindelser, fremgangsmåte forfremstilling derav, deres anvendelse som et medikament samtfarmasöytiske preparater inneholdende forbindelsene
NO20035298D0 (no) CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
NO20040356L (no) Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling.
NO20032733L (no) Difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse
DK1180518T3 (da) 5-pyridyl-1,3-azolforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK1202965T3 (da) Indolderivater, fremgangsmåde til fremstilling deraf, farmaceutiske præparater indeholdende disse og deres medicinske anvendelse
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
DK1417206T3 (da) Hidtil ukendte 2H-pyridazin-3-on-derivater, farmaceutiske præparater indeholdende det samme, og en fremgangsmåde til fremstilling af den aktive bestanddel
NO20031273D0 (no) Substituerte kanelsyreguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som legemiddel og legemiddel som inneholder de samme
DK1381351T3 (da) Fremgangsmåde til kontinuerlig fremstilling af inhalerbare medikamenter
DK1144386T3 (da) Polymorf form af telmisartan, fremgangsmåde til fremstilling deraf og anvendelse deraf til fremstilling af et lægemiddel
DK1537096T3 (da) Derivater af dioxan-2-alkylcarbamater, fremstilling og terapeutisk anvendelse heraf
DK1230230T3 (da) Derivater af indeno-dihydrothiazol, fremstilling deraf og anvendelse som anorektiske lægemidler
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
IS7424A (is) Oxasólídínónafleiður, aðferðir til að framleiða þær og lyfjablöndur sem innihalda þær
DK1696913T3 (da) Vinfluninholdigt farmaceutisk præparat til parenteral administration, fremgangsmåde til fremstilling deraf og dets anvendelse
NO20033120L (no) 2-arylimino-2,3-dihydrotiazolderivater, fremgangsmåter for fremstilling derav og terapeutisk anvendelse derav
NO20042890L (no) Farmasoytiske preparater og fremgangsmate for fremstilling derav
NO20053805D0 (no) Diarylmetylindenpiperidinderivater, framgangsmate for fremstilling derav, og anvendelse derav